Arrowstreet Capital, Limited Partnership Biocryst Pharmaceuticals Inc Transaction History
Arrowstreet Capital, Limited Partnership
- $136 Billion
- Q2 2025
A detailed history of Arrowstreet Capital, Limited Partnership transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 4,278,555 shares of BCRX stock, worth $35.7 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
4,278,555
Previous 194,152
2103.71%
Holding current value
$35.7 Million
Previous $1.46 Million
2532.9%
% of portfolio
0.03%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding BCRX
# of Institutions
315Shares Held
202MCall Options Held
928KPut Options Held
560K-
Vanguard Group Inc Valley Forge, PA20.5MShares$172 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$167 Million0.0% of portfolio
-
State Street Corp Boston, MA8.51MShares$71 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.46MShares$70.7 Million9.06% of portfolio
-
Alkeon Capital Management LLC New York, NY5.71MShares$47.7 Million0.09% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.55B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...